This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.
Research
Latest papers
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective.
The Journal of antimicrobial chemotherapy · 2026
Ecological footprint of salbutamol administration by metered-dose inhaler versus nebulisation in acute asthma: a life-cycle assessment.
JRSM open · 2025
Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models.
Pharmaceutics · 2025
Latest funding
- $1,262,250
Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements
CIHR · 2026 · Principal investigator
- $891,226
L'AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1
CIHR · 2021 · Co-investigator
- $640,473
The role of ectonucleotidase in the calcification of the aortic valve
CIHR · 2011 · Co-investigator
27 publications.
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective.
Porlier A, Nadeau M, Laflamme J, Pilote S, Gervais P, Drolet B, Tchernof A, Biertho L, Marceau S, Simard C, Julien F
Ecological footprint of salbutamol administration by metered-dose inhaler versus nebulisation in acute asthma: a life-cycle assessment.
Berthelot S, Ménard JF, Bélanger-Chabot G, Arias Garcia G, Mantovani D, Simard C, Guertin JR, Marx T, Bluteau A
Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models.
Chavez Alvarez AC, Bouzriba C, Ouellette V, Gagné-Boulet M, Patenaude A, Pilote S, C-Gaudreault R, Simard C, Fortin S
A Physicochemical Stability Study of Pembrolizumab Vial Leftovers: Let Us Stop Pouring Good Money Down the Drain.
Porlier A, Gagnon PY, Chénard V, Veillette M, Bertrand N, Duchaine C, Simard C, Drolet B
Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable?
Duong A, Simard C, Williamson D, Marsot A
Stability of Opened Durvalumab (IMFINZI) Vials. The Beginning of the End of Costly Product Wastage?
Porlier A, Gagnon PY, Chénard V, Veillette M, Bertrand N, Duchaine C, Michael NJ, Simard C, Drolet B
Overview of Cardiac Arrhythmias and Treatment Strategies.
Kingma J, Simard C, Drolet B
Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations.
El Hassani M, Thirion DJG, Koloskoff K, Matouk E, Simard C, Cloutier I, Pilote S, Marsot A
Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Improves Their Stability in Rodent Liver Microsomes.
Chavez Alvarez AC, Bouzriba C, Moreau E, Auzeloux P, Besse S, Ouellette V, Zarifi Khosroshahi M, Côté MF, Pilote S, Miot-Noirault E, Chezal JM, Simard C, C-Gaudreault R, Fortin S
Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects.
Pilote S, Simard C, Drolet B
Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements
Principal investigators: Fortin, Sébastien; Benoit-Biancamano, Marie-Odile; C.-Gaudreault, René; Diorio, Caroline; Droit, Arnaud; Durocher, Francine; Moreau, Emmanuel; Simard, Chantale
Keywords: Antimitotiques; Cancers Colorectaux; Cancers Colorectaux Métastatiques Et Chimiorésistants; Chimiothérapie Personnalisée; Développement De Médicaments Anticancéreux; Modulateurs D'Ahr; Promédicaments Antimicrotubules
L'AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1
Principal investigators: Fortin, Sébastien
Keywords: Antimitotiques; Cancers Du Sein; Cancers Du Sein Chimiorésistants; Cancers Du Sein Triple Négatifs; Chimiothérapie Personnalisée; Développement De Médicaments Anticancéreux; Promédicaments Antimicrotubules
The role of ectonucleotidase in the calcification of the aortic valve
Principal investigators: Mathieu, Patrick
Keywords: Calcific Aortic Valve Disease; Calcification; Diabetes; Ectonucleotidase; Hypertension; Insulin Resistance
Caractérisation de la sous-famille des cytochromes P450 2C chez le cobaye
Principal investigators: Hasibu, Ibrahim
Keywords: Biotransformation; Cardiologie; Cytochromes P450; Hplc; Immunobuvardage; Interactions; Médicaments; Pharmacocinétique; Pharmacologie; Rt-Pcr Et Pcr
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Médecine
- Surgery
- Family Medicine and Emergency Medicine
- Other
Co-authors at Université Laval, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Paul Poirier
Médecine
2 shared papers, latest 2007
Nicolas Bertrand
Faculty
2 shared papers, latest 2025
Christian Steinberg
Faculty
1 shared papers, latest 2021
Patrick Mathieu
Surgery
1 shared papers, latest 2012
Simon Berthelot
Family Medicine and Emergency Medicine
1 shared papers, latest 2025
David Williamson
Faculty
1 shared papers, latest 2022
Laurent Biertho
Faculty
1 shared papers, latest 2026
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.